2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Jubilee Brown, MD, professor, director, Gynecologic Oncology, Levine Cancer Institute, Atrium Health, discusses the clinical implications of the phase 3 PRIMA trial (NCT02655016) in advanced ovarian cancer.
The PRIMA trial evaluated the PARP inhibitor niraparib (Zejula) vs placebo as frontline maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy. Ultimately, the results of the trial indicated that niraparib outperformed placebo in terms of progression-free survival irrespective of the presence or absence of homologous recombination deficiency (HRD).
The all-comer benefit observed informs clinical decisions, Brown explains. After frontline platinum-based chemotherapy, patients should be considered for treatment with niraparib independent of the presence or absence of germline or somatic BRCA mutations or HRD, Brown concludes.
Related Content: